Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly : CHMP Recommends Approval of Baricitinib in Atopic Dermatitis

share with twitter share with LinkedIn share with facebook
09/18/2020 | 08:49am EDT

By Michael Dabaie

 

Eli Lilly & Co. and Incyte said the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion for baricitinib for the treatment of adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy.

The opinion marks the first step toward European regulatory approval for baricitinib, marketed as Olumiant, for patients with atopic dermatitis.

The CHMP opinion is now being referred for action to the European Commission, which grants approval in the European Union. A final decision is expected from the European Commission in the next one to two months, the companies said.

Olumiant is already approved in more than 70 countries as a treatment for adults with moderately to severely active rheumatoid arthritis. Lilly has exclusive worldwide development and commercialization rights for baricitinib and some follow-on compounds for patients with inflammatory and autoimmune diseases under a license and collaboration agreement with Incyte.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 


Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY -1.58% 130.46 Delayed Quote.-0.74%
INCYTE CORPORATION -0.44% 86.64 Delayed Quote.-0.78%
share with twitter share with LinkedIn share with facebook
All news about ELI LILLY AND COMPANY
10:46aEADV 2020 : Lilly and Incyte Showcase New Data for Baricitinib for the Treatment..
PR
10/30ELI LILLY AND COMPANY : - New Data at EADV 2020 Confirm Taltz Demonstrates Susta..
AQ
10/30FALL CLINICAL DERMATOLOGY 2020 : Lilly and Incyte Showcase Positive New Data for..
PR
10/29ELI LILLY AND : US to receive 300,000 vials of experimental COVID-19 antibody th..
AQ
10/29ELI LILLY AND : HHS, DOD Collaborate on Plans to Purchase of Lilly Investigation..
AQ
10/29ELI LILLY AND COMPANY : - Data for Lilly's bamlanivimab in COVID-19 outpatients ..
AQ
10/29ELI LILLY AND : Lilly announces agreement with U.S. government to supply 300,000..
AQ
10/29ELI LILLY AND : New Data at EADV 2020 Confirm Taltzģ (ixekizumab) Demonstrates S..
PR
10/28ELI LILLY AND : Submits New Data on Covid-19 Treatment Drug
DJ
10/28REGENERON PHARMACEUTICALS : says its COVID-19 antibody treatment cut medical vis..
RE
More news
Financials (USD)
Sales 2020 23 723 M - -
Net income 2020 6 107 M - -
Net Debt 2020 11 184 M - -
P/E ratio 2020 20,2x
Yield 2020 2,27%
Capitalization 118 B 118 B -
EV / Sales 2020 5,46x
EV / Sales 2021 4,90x
Nbr of Employees 33 625
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 165,83 $
Last Close Price 130,46 $
Spread / Highest target 53,3%
Spread / Average Target 27,1%
Spread / Lowest Target -8,02%
EPS Revisions
Managers
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Joshua L. Smiley Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Chief Information & Digital Officer, Senior VP
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY-0.74%120 167
JOHNSON & JOHNSON-6.01%361 159
ROCHE HOLDING AG-6.13%275 049
PFIZER INC.-9.44%196 047
MERCK & CO., INC.-17.31%191 944
NOVARTIS AG-22.21%177 493